Valneva SE (VALN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the technical indicators show some bullish signals, there is no significant trading trend, news, or financial data to support a strong entry point. Additionally, no proprietary trading signals or congressional trading data are available to provide further conviction.

Technical Analysis

The MACD is positive at 0.126, indicating a bullish momentum, but it is contracting. The RSI is neutral at 52.199, showing no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near a key support level (S1: 10.157). However, there is no strong confirmation of a breakout or reversal.

Positive Catalysts

Bullish moving averages and positive MACD suggest some upward momentum.

Neutral/Negative Catalysts

No recent news, financial data, or significant trading trends from hedge funds or insiders. The RSI is neutral, and there are no proprietary trading signals to support a strong buy.

Financial Performance

No financial data available for assessment.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for trend analysis or recent analyst ratings.

2 Analyst Rating

Wall Street analysts forecast VALN stock price to fall

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 10.920

Low

7.55

Averages

10.28

High

Current: 10.920

Low

7.55

Averages

10.28

High

Guggenheim

Buy

downgrade

$14 -> $13

AI Analysis

2025-09-08

Reason

Guggenheim

Price Target

$14 -> $13

AI Analysis

2025-09-08

downgrade

Buy

Reason

Guggenheim lowered the firm's price target on Valneva to $13 from $14 and keeps a Buy rating on the shares following the company's recent first half earnings release and the suspension of the Ixchiq BLA in the U.S. Given the suspension, the firm is removing all U.S. Ixchiq sales from its model and also assumes more limited commercial uptake in Europe, but it maintains a Buy rating ahead of the "important" Phase 3 data readout for their Lyme vaccine that it expects by late Q4 or in early Q1 of 2026.

Jefferies

Maury Raycroft

Buy

downgrade

$18 -> $14

2025-08-25

Reason

Jefferies

Maury Raycroft

Price Target

$18 -> $14

2025-08-25

downgrade

Buy

Reason

Jefferies analyst Maury Raycroft lowered the firm's price target on Valneva to $14 from $18 and keeps a Buy rating on the shares after the FDA suspended the Ixchiq biologics license application based on four new serious adverse events seen outside of the U.S. The firm, which thinks there is some potential risk for ex-U.S. regulators to change their stance on Ixchiq licensure, adds that Ixchiq is "not a major revenue driver" in the near term.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VALN

Unlock Now

VALN Should I Buy

VALN Should I Buy

Should You Buy Valneva SE (VALN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch